Canada-based biotechnology company Kane Biotech announced that DispersinB-Gentamicin combination wound gel spray has passed the primary skin irritation tests.
The test was aimed at determining the dermal irritation potential of the spray as required by the FDA for biocompatibility.
The biocompatibility study, which was conducted on the combination of DispersinB antibiofilm enzyme and the broad-spectrum antibiotic Gentamicin, demonstrated that DispersinB-Gentamicin wound gel spray does not cause dermal erythema or edema due to skin irritation.
Kane Biotech has two DispersinB-based wound gel spray formulations in development for the topical wound care market.
The first product is the DispersinB-Gentamicin wound gel spray for topical wound care in both human and veterinary applications while the second wound care product is in collaborative development with the US Army Institute of Surgical Research for combat wound infections.
DispersinB-antimicrobial combinations have proved to be effective against Methicillin-resistant Staphylococcus aureus (MRSA) when related with human wound infections.
